LIFE SCIENCES & PHARMACEUTICALS VENTURE CAPITAL INFORMATION & STATS
Financing in the healthcare field has significantly increased over the years. With changes and market-shifting innovations in biotechnology, medical devices, drug delivery, drug discovery, and medical technologies, funding has become necessary in order to capitalize on and commercialize solutions.
Pharmaceuticals venture capital firms fund seed stage, early stage, and late stage companies. As one of the most profitable industries in the United States, it has one of the largest demands for ongoing patenting and research and development, which makes pharmaceuticals funding critical. Based on the continuously emerging products and solutions, pharmaceuticals private equity is also vital in supporting the important and large-scale mergers and acquisitions that normally take place between smaller and larger pharma companies.
Life sciences venture capital firms have backed and created a large market for major disciplines in the field including biotechnology, biochemistry, biomedical sciences, medical devices, genetics, and food sciences. Start ups in this field can prove profitable for investor and entrepreneur alike due to the high potential for acquisition by larger life sciences and pharmaceuticals companies. Like the broad field of technology, life sciences private equity is a way to sustain businesses and build a competitive advantage.
Submit your business plan to FindVenture.com to get access to life sciences funding and pharmaceuticals private equity.
Featured Investors
Johnston Associates focuses on high-potential pharmaceutical and biotechnology businesses in the Princeton, New Jersey area, providing seed stage funding and aiding in raising follow-on investments. Johnston Associates Inc. typically chooses one enterprise to invest in per year with financing amounts ranging from $300,000 to $3 million+.
Foundation Capital was formed in 2005 as a subsidiary of the New Jersey Health Foundation to back seed stage companies within the healthcare and life sciences area focused on proprietary and emerging products and technologies.
Baird Private Equity backs businesses through venture capital needs, growth equity, and leveraged buyouts within the business service, manufactured product, and healthcare/life science sectors. The company provides investments to companies in the United States, Europe, and Asia.
Growth Fund Private Equity is a subsidiary of the Southern Ute Growth Fund, which is a $2 billion fund owned by Southern Ute Indian Tribe. The company focuses on technology, software, medical devices, life sciences, telecommunications, media, natural resources, government, defense, and financial services. Growth Fund Private Equity provides early stage venture capital, leveraged buyouts, and other types of equity.
Fidelity Biosciences is a subsidiary of Fidelity Investments, investing in biopharmaceutical and medical technology companies. Companies within their portfolio include EnVivo Pharmaceuticals, NextWave, and Tetraphase Pharmaceuticals.
3i Private Equity Investment Funds is an international investment firm backing high-growth, high-potential businesses in the areas of industrials and energy, healthcare, business and financial services, technology, media, telecommunications, and consumer goods. 3i Private Equity Investment Funds normally invests in companies in diverse stages of development.
MB Venture Partners backs life sciences companies, including medical device and biotechnology, in all development stages, usually within the midwest and southeast regions, establishing itself as both a player within midwest and southeast venture capital firms. The company has particular interest in products for musculoskeletal disease and tends to serve as one of the most prominent early venture capital firms meanwhile offering seed stage funding as well.
Aisling Capital is a life sciences private equity firm investing in emerging products and technologies across the world. The company focuses on multiple stages of development and provides investments ranging from $20 million to $50 million with the opportunity for follow-on investments. Companies in their portfolio include Aragon Pharmaceuticals and Transenterix.
Versant Ventures is a venture capital firm with more than $1.6 billion in committed capital and specializes in investments for companies within healthcare services/IT, biotechnology, medical devices, and pharmaceuticals. Versant Ventures currently has a portfolio of 75 companies.
